LHC Group (NASDAQ:LHCG) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday, January 9th.
According to Zacks, “LHC Group is the preferred post-acute care partner for hospitals, physicians and families nationwide. From home health and hospice care to long-term acute care and community-based services, LHC delivers high-quality, cost-effective care that empowers patients to manage their health at home. More than 60 leading hospitals and health systems around the country have partnered with LHC Group to deliver patient-centered care in the home. More hospitals, physicians and families choose LHC Group, because our 13,000-plus employees in 26 states are united by a single, shared purpose: It’s all about helping people. “
Several other brokerages have also issued reports on LHCG. Robert W. Baird restated a “hold” rating and set a $69.00 target price on shares of LHC Group in a research report on Friday, November 10th. Royal Bank of Canada boosted their price target on LHC Group from $70.00 to $81.00 and gave the company an “outperform” rating in a report on Tuesday, November 7th. Oppenheimer boosted their price target on LHC Group from $68.00 to $80.00 and gave the company an “outperform” rating in a report on Tuesday, November 7th. Jefferies Group boosted their price target on LHC Group from $68.00 to $83.00 and gave the company a “buy” rating in a report on Tuesday, November 7th. They noted that the move was a valuation call. Finally, Craig Hallum reiterated a “buy” rating and issued a $80.00 price target (up previously from $67.00) on shares of LHC Group in a report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $77.10.
LHC Group (LHCG) traded up $1.00 during trading hours on Tuesday, reaching $65.86. The company’s stock had a trading volume of 241,641 shares, compared to its average volume of 289,600. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $1,200.00, a PE ratio of 28.39, a PEG ratio of 1.69 and a beta of 0.70. LHC Group has a twelve month low of $44.13 and a twelve month high of $76.14.
LHC Group (NASDAQ:LHCG) last issued its earnings results on Monday, November 6th. The health services provider reported $0.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.60 by $0.04. The firm had revenue of $272.90 million for the quarter, compared to analysts’ expectations of $265.35 million. LHC Group had a return on equity of 9.52% and a net margin of 4.09%. The business’s revenue was up 18.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.54 earnings per share. research analysts forecast that LHC Group will post 2.4 EPS for the current year.
Hedge funds have recently modified their holdings of the company. Federated Investors Inc. PA grew its holdings in shares of LHC Group by 4.2% during the second quarter. Federated Investors Inc. PA now owns 1,622 shares of the health services provider’s stock valued at $110,000 after buying an additional 66 shares during the last quarter. Acrospire Investment Management LLC grew its holdings in shares of LHC Group by 30.8% during the second quarter. Acrospire Investment Management LLC now owns 1,700 shares of the health services provider’s stock valued at $115,000 after buying an additional 400 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of LHC Group by 758.0% during the second quarter. Cubist Systematic Strategies LLC now owns 1,716 shares of the health services provider’s stock valued at $116,000 after buying an additional 1,516 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of LHC Group during the third quarter valued at $163,000. Finally, ETRADE Capital Management LLC purchased a new stake in shares of LHC Group during the second quarter valued at $219,000. 85.41% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “LHC Group (NASDAQ:LHCG) Downgraded by Zacks Investment Research to “Sell”” was originally published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.truebluetribune.com/2018/01/18/lhc-group-lhcg-downgraded-to-sell-at-zacks-investment-research.html.
About LHC Group
LHC Group, Inc is a holding company. The Company provides post-acute healthcare services to patients through its home nursing agencies, hospice agencies, community-based services agencies and long-term acute care hospitals (LTACHs). The Company operates through four segments: home health services, hospice services, community-based services and facility-based services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.